Abstract
CFTR modulators, in particular elexacaftor/tezacaftor/ivacaftor (ETI) has widely reported health benefits in eligible people with CF (pwCF). This study aims to determine the effect of the introduction of ETI on positive PsA culture in sputum and cough swabs in pwCF and any effect on ciprofloxacin susceptibility. ETI was started on 92% of eligible pwCF by the end of September 2020.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Paper Title
Journal
Date
